Home Page Overall Ranking ROE Ranking P/E Ranking Dividend Yield Capitalization Our eBook Our Book Contact










Isin US4781601046
Ticker JNJ
Company JOHNSON & JOHNSON
Currency $
Price
Aware Investor Index (AII) 4.7110
Recommendation BUY
P/E 27.62
ROE 17.70 %
Capitalization 347,758,827,000 $
Dividend Yield 2.39 %
P/S 4.96
AII Position 141
P/E Position 349
ROE Position 196
Capitalization Position 9
Dividend Yield Position 268
Sales 70,074,000,000 $
10-Year Average Earnings 12,592,700,000 $
Shares Outstanding 2,812,900,000
Equity 71,150,000,000 $
Dividend per Share 2.95 $
Industry Personal Care
Country United States
JOHNSON & JOHNSON Investor Relations Web Site http://www.investor.jnj.com/investor-relations.cfm







Sales:

YEAR MONTH AMOUNT
2015 12 70,074,000,000.00 $
2014 12 74,331,000,000.00 $
2013 12 71,312,000,000.00 $

Earnings:

YEAR MONTH AMOUNT
2015 12 15,409,000,000.00 $
2014 12 16,323,000,000.00 $
2013 12 13,831,000,000.00 $
2012 12 10,514,000,000.00 $
2011 12 9,672,000,000.00 $
2010 12 13,334,000,000.00 $
2009 12 12,266,000,000.00 $
2008 12 12,949,000,000.00 $
2007 12 10,576,000,000.00 $
2006 12 11,053,000,000.00 $

Equity:

YEAR MONTH AMOUNT
2015 12 71,150,000,000.00 $
2014 12 69,752,000,000.00 $
2013 12 74,053,000,000.00 $
2012 12 64,826,000,000.00 $
2011 12 57,080,000,000.00 $

Shares Outstanding:

YEAR MONTH AMOUNT
2015 12 2,812,900,000
2014 12 2,863,900,000
2013 12 2,877,000,000
2012 12 2,812,600,000
2011 12 2,775,300,000

 












Bloomberg News for JOHNSON & JOHNSON:

Apr 17, 2018
Johnson & Johnson Earnings: Fine For Now
medicine facing generic competition in Europe. This may eventually weigh on JNJ's growth.Disappointing Actelion results leave JNJ even more dependent on the rest of its pharma unit. Fortunately, the news...
Apr 16, 2018
Awful Price Action on Banks a Bad Omen for Netflix: Taking Stock
LRCX tomorrow followed by European giant ASML the following morning), big pharma and medtech (JNJ, ABT and ISRG over next couple days plus a ton of data out of the American Association for Cancer...
Apr 16, 2018
Bristol-Myers Partners With Janssen on Anticlotting Therapy
is exploring broader uses for its anticoagulant, Xarelto, and has an injectible anticoagulant, JNJ-9375, in its pipeline. “It’s really a next-generation approach that we’re very excited about.”...
Feb 21, 2018
Sell Side Says Chill Out on Alarming Yield Talk: Taking Stock
names such as CAH, CELG, DVAX (also awaiting update from CDC on Heplisav-B today), GILD, INCY, JNJ, RVNCEnergy: EnerCom in Dallas begins while International Petroleum Week rolls on...
Feb 14, 2018
How Markets Might React to Today's Key CPI Data
WU, YELPLeerink Global Healthcare Conference in NYC starts today with AMGN, BIIB, BLUE, GBT, JNJ, PBYI, SAGEStifel Transportation and Logistics Conference in Miami with GBX, GWR, LSTR, YRCWCredit...
Aug 4, 2010
Arbitrage Profit in U.S. Takeovers Pending on Aug. 4
09/30/10 BSMD US MMSI US 4.38 4.35 0.03 0.69 30,433 Cash 09/30/10 MEND US JNJ US 23.40 23.24 0.16 0.69 168,901 Cash 12/31/10 ODSY US GTIV US 27.00 ...
Aug 31, 2010
Indicated Dividend Yield Ranking for the S&P 500 by Industry
54 0.18 58.5 MRK Merck & Co Inc 4.38 0.38 156.8 JNJ Johnson & Johnson 3.77 0.54 43.2 ABT Abbott Laboratories ...
Jan 25, 2011
U.S. Stock Options With Biggest Changes in Implied Volatility
320 JNJ JOHNSON&JOH JNJ US 02/19/11 C60 -17.9 14.0 1.48 -43.1 5406 UNG US NAT GAS UNG US 02/19/11 C5 -17.8 38.2 1.12 -9.7 1068 JNJ JOHNSON&JOH JNJ US 02/19/11...
Jan 3, 2011
U.S. Stock Options With Biggest Changes in Implied Volatility
Volume ============================================================================= JNJ JOHNSON&JOH JNJ US 02/19/11 P65 159.3 16.3 2.72 -23.4 2170 IWM ISHARES-RUS IWM US 01/22/11...
Sep 30, 2013
Bard, Vaginal-Mesh Makers, Said to Be in Settlement Talks
this year. Boston Scientific also rose 1.4 percent to $11.68 in New York trading at 11:36 a.m. JNJ fell 4 cents to $86.69 while Bard fell 81 cents to $114.93. Endo rose 4 cents to $45.65 in Nasdaq...


Google News for JOHNSON & JOHNSON:

StockNews.com (blog) - 1 day ago
Johnson & Johnson (JNJ) Loses Another Asbestos Case Related to ...
Johnson & Johnson (NYSE:JNJ) has lost another major case related to allegations that one of its products led to the development of cancer.
FiercePharma
J&J hit with $21.7 million verdict in another talc asbestos cancer case
J&J hit with $21.7 million verdict in another talc asbestos cancer case ... Johnson & Johnson and its talc suppliers on Wednesday were hit with ...
Bloomberg
Johnson & Johnson (JNJ) Ex-Dividend Date Scheduled for May 25 ...
Johnson & Johnson ( JNJ ) will begin trading ex-dividend on May 25, 2018. A cash dividend payment of $0.9 per share is scheduled to be paid ...
Proactive Investors USA & Canada
Johnson & Johnson (JNJ) Presents at UBS Health Care Brokers ...
Johnson & Johnson (NYSE:JNJ) UBS Health Care Conference May 21, 2018 10:00 AM ET. Executives. Matt Stuckley - IR. Sandra Peterson ...
CNBC - 1 day ago
Johnson & Johnson to relaunch baby-care line after its 20% sales ...
So J&J is cutting the number of ingredients in the new Johnson's Baby line by half, eliminating dyes and sulfates and replacing ingredients like ...
Bloomberg
Johnson & Johnson (JNJ) Consumer and Medical Devices Business ...
Johnson & Johnson (NYSE:JNJ). Company Conference Presentation. May 00, 2018, 08:30 AM ET. Executives. Joseph Wolk - Vice President, ...
Nasdaq - 1 day ago
Johnson & Johnson (JNJ) Gets Bad News on Alzheimer's Drug ...
Johnson & Johnson (NYSE:JNJ) had high hopes for an experimental Alzheimer's drug named Atabecestat, but the pharmaceutical giant is now ...
Equities.com
Johnson & Johnson (NYSE:JNJ): Ex-Dividend Is In 3 Days, Should ...
If you are interested in cashing in on Johnson & Johnson's (NYSE:JNJ) upcoming dividend of $0.9 per share, you only have 3 days left to buy ...
StockNewsJournal
Varied Analyst Comments On Johnson & Johnson (JNJ), Kimco ...
Johnson & Johnson (NYSE:JNJ) trading capacity remained 6.89 million shares during the last session. However, the volume average of the last ...
Investorplace.com
J&J CEO warns of 'unintended consequences' of Trump's drug-price ...
However, Gorsky expects J&J's pharma business to successfully ... Johnson & Johnson Chairman and CEO Alex Gorsky told CNBC on ...


Back